Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fe2+-heme in the digestive vacuole refers to the ferrous (Fe2+) form of the heme molecule liberated during hemoglobin digestion by malaria parasites such as *Plasmodium falciparum*. The digestive vacuole acts as a lysosome-like organelle where proteases break down hemoglobin; the resulting free heme (primarily in the Fe2+ oxidation state) is highly toxic to the parasite. The parasite converts it to an inert crystalline form called hemozoin; inhibition of this biocrystallization is the basis for several key antimalarial drug classes, including chloroquine. Fe2+-heme itself is not a receptor, enzyme, or protein but a molecular species and a critical intermediary in *Plasmodium* biology—its accumulation or improper detoxification is a validated target for antimalarial chemotherapy. This target is atypical (not a conventional protein drug target), and the entry may be considered non-standard or “incorrect” by strict pharmacological target nomenclature[1].
Inhibition of heme biocrystallization (blockade of hemozoin formation) Accumulation of toxic Fe2+-heme in the vacuole, leading to parasite death
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fe2+-heme in digestive vacuole.